For millions of people living with retinitis pigmentosa, the progression of the disease is often a slow, relentless march toward legal blindness. However, new long-term data suggests a potential turning point in how we treat this devastating form of retinal degeneration. Results from a three-year follow-up study indicate that a novel optogenetic therapy, MCO-010, can provide durable and clinically meaningful vision improvements for patients suffering from severe vision loss.
The findings, released by Nanoscope Therapeutics, stem from the REMAIN study. This study served as the long-term extension of the Phase 2b/3 RESTORE trial, specifically evaluating the efficacy and safety of MCO-010 in patients with retinitis pigmentosa (RP). The results are particularly significant because they demonstrate that vision gains are not merely temporary but can be sustained over a period of several years.
As a physician and health journalist, I have seen many “breakthroughs” in ophthalmology that fail to hold up over time. What makes the MCO-010 data compelling is the duration of the effect. In a population where the natural history of the disease is characterized by steady decline, the ability to restore and maintain visual function represents a substantial shift in the therapeutic landscape for retinal diseases.
Sustained Gains: The REMAIN Study Results
The primary objective of the REMAIN study was to track the long-term impact of a single intravitreal injection of MCO-010. The data revealed that patients maintained an average Best Corrected Visual Acuity (BCVA) gain from baseline of approximately 0.3 LogMAR through Week 152 (equivalent to three lines or 15 letters on a standard ETDRS vision chart).
To put this into perspective, a three-line gain on a vision chart is not just a statistical victory; it is a functional one. For a patient with severe vision loss, these additional letters can mean the difference between being unable to read a sign and regaining the ability to navigate their environment more independently. The study confirms these gains were maintained through the 152-week mark, suggesting a durable response to the one-time treatment.
Beyond efficacy, the company reported a favorable safety and tolerability profile throughout the three-year period. This is critical for any gene-based or optogenetic therapy, as the long-term interaction between the synthetic proteins and the retinal tissue must be carefully monitored to ensure no delayed adverse reactions occur.
Understanding the Impact of Optogenetic Therapy
Retinitis pigmentosa typically involves the progressive loss of photoreceptors—the cells in the retina that convert light into electrical signals for the brain. Once these cells are gone, the eye loses its ability to “see,” regardless of how healthy the rest of the optic nerve may be. Optogenetics seeks to bypass this loss by introducing light-sensitive proteins into the remaining retinal cells, effectively turning them into new photoreceptors.
A key distinction of MCO-010 is that it is designed as a disease-agnostic therapy. Unlike some gene therapies that target a specific genetic mutation—meaning only a small percentage of the RP population can benefit—a disease-agnostic approach targets the common end-stage result of photoreceptor loss. This means the therapy has the potential to help a much broader range of patients, regardless of the specific genetic cause of their blindness.
The clinical significance of this is underscored by Dr. Allen C. Ho, Director of Retina Research at Wills Eye Hospital and Chief Medical Advisor for Nanoscope. Dr. Ho noted that patients with this condition typically lose about 1.5 lines of vision every five years and often reach legal blindness as early as age 20. He described the ability to not only slow this loss but to restore visual function for several years as a “significant therapeutic advance.”
The Path to Regulatory Approval
The success of the REMAIN study has provided the clinical foundation for Nanoscope Therapeutics to move toward commercialization. In June 2025, the company initiated a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) .
If approved, MCO-010 would have the potential to be the first FDA-approved optogenetic therapy. The “rolling” nature of the BLA allows the company to submit completed sections of the application as they become available, rather than waiting until every single piece of data is finalized, which can often accelerate the review process for therapies targeting unmet medical needs.
For the global medical community, this represents a proof-of-concept for the MCO platform. The ability to utilize a one-time injection to treat severe vision loss across different forms of retinal degeneration could pave the way for similar treatments for other blinding conditions that currently have no cure.
Key Takeaways from the MCO-010 Study
- Durable Efficacy: Patients showed an average gain of 0.3 LogMAR (3 lines on a vision chart) sustained through 152 weeks.
- Disease-Agnostic: The therapy targets photoreceptor loss generally, rather than a specific genetic mutation.
- Administration: The treatment is delivered via a single intravitreal injection.
- Regulatory Status: A rolling Biologics License Application (BLA) was initiated in June 2025.
- Patient Profile: The study focused on patients with severe vision loss due to retinitis pigmentosa.
The next major milestone for this therapy will be the FDA’s review of the Biologics License Application. While a specific decision date has not been publicly detailed, the initiation of the rolling submission in mid-2025 suggests the regulatory process is well underway. We will continue to monitor the FDA’s progress and any subsequent updates regarding the availability of MCO-010 for clinical use.
Do you or a loved one live with retinitis pigmentosa? We invite you to share your thoughts or questions about these developments in the comments below.